Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-10-16

Clinical Trial Update: Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy [Phase 1]

View source ↗

Summary

A Phase 1 trial of an anti-VEGFR vaccine therapy for neovascular age-related macular degeneration (neovascular maculopathy) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Anti-VEGFR vaccine therapy

Snippet

Sponsor: Osaka University | Conditions: Neovascular Maculopathy, Age Related Macular Degeneration | Phase 1 | Status: COMPLETED